Emerging therapies for COVID-19 pneumonia
On 11 March 2020, the World Health Organization declared coronavirus disease 2019
(COVID-19) a pandemic. In recent months, with the spread of COVID-19, there has been …
(COVID-19) a pandemic. In recent months, with the spread of COVID-19, there has been …
[HTML][HTML] SARS‐CoV‐2 virus infection: targets and antiviral pharmacological strategies
DM de Oliveira Campos, UL Fulco… - Journal of evidence …, 2020 - ncbi.nlm.nih.gov
The current pandemic of coronavirus disease 2019 (COVID-19) poses a threat to global
public health owing to its high rate of spread and its association with severe forms of …
public health owing to its high rate of spread and its association with severe forms of …
[HTML][HTML] Therapeutic options for COVID-19: a review
R Pujari, MV Thommana, BR Mercedes, A Serwat - Cureus, 2020 - ncbi.nlm.nih.gov
An acute respiratory disease caused by a novel coronavirus [severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019-nCoV], the coronavirus …
syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019-nCoV], the coronavirus …
A comprehensive review on potential therapeutics interventions for COVID-19
COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, a new beta
coronavirus that emerged in Wuhan, China. Being primarily a respiratory disease, it is highly …
coronavirus that emerged in Wuhan, China. Being primarily a respiratory disease, it is highly …
Pipeline pharmacological therapies in clinical trial for COVID-19 pandemic: a recent update
The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2),
responsible for causing coronavirus disease 2019 (COVID-19), marked the third time in the …
responsible for causing coronavirus disease 2019 (COVID-19), marked the third time in the …
Current and future therapeutical approaches for COVID-19
Coronavirus 2019 (COVID-19), the WHO-classified novel coronavirus of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly become a global pandemic …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly become a global pandemic …
Drugs for COVID-19: An update
J Ceramella, D Iacopetta, MS Sinicropi, I Andreu… - Molecules, 2022 - mdpi.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the seventh
known human coronavirus, and it was identified in Wuhan, Hubei province, China, in 2020. It …
known human coronavirus, and it was identified in Wuhan, Hubei province, China, in 2020. It …
[HTML][HTML] An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics
D Wang, Z Li, Y Liu - Journal of infection and public health, 2020 - Elsevier
Since a novel coronavirus pneumonia outbreak in late December 2019, coronavirus disease-
19 (COVID-19) epidemic has gradually spread worldwide, becoming a major public health …
19 (COVID-19) epidemic has gradually spread worldwide, becoming a major public health …
Current therapeutics for COVID-19, what we know about the molecular mechanism and efficacy of treatments for this novel virus
D Narayanan, T Parimon - International journal of molecular sciences, 2022 - mdpi.com
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has caused significant
morbidity and mortality worldwide. Though previous coronaviruses have caused substantial …
morbidity and mortality worldwide. Though previous coronaviruses have caused substantial …
Pathophysiology and potential therapeutic candidates for COVID-19: a poorly understood arena
A Samaddar, M Grover, VL Nag - Frontiers in pharmacology, 2020 - frontiersin.org
Coronavirus disease 2019 (COVID-19), an acute onset pneumonia caused by a novel
Betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged …
Betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged …